CTI Life Sciences Fund Launches Oligon Therapeutics

‍

CLINIC HERE TO SEE FULL PRESS RELEASE

Total investments of $14 million by CTI, the Fonds de solidarité FTQ, and Investissement Québec

‍

Montreal, Quebec, September 22, 2025 – CTI Life Sciences Fund (CTI) has launched Oligon Therapeutics (OligonTx), a new biotechnology company pioneering RNA-based multi-targeting drugs as novel treatments for oncology, immunology, and other diseases. Oligon’s proprietary SeekR™ technology platform represents the next generation of self-delivering therapeutic siRNA conjugates. CTI, along with co-investors Investissement Québec (IQ) and Fonds de Solidarité FTQ (FSTQ), has initially committed US $14 million to OligonTx to launch operations in Montreal, Quebec, and to develop a pipeline of SeekR™ therapeutics. The current pipeline includes two wholly owned therapeutic programs that reprogram specific immune cell subtypes. OligonTx also has a growing pipeline of partnered therapeutic programs with biopharma and academic collaborators, primarily targeting different types of cancer cells. OligonTx will also partner with additional pharma industry collaborators to further expand into additional new indications.

‍

‍

‍

‍